疼痛管理薬の世界市場 - 2025年～2033年

疼痛管理薬の世界市場は、2023年に597億1,000万米ドルに達し、2032年には1,133億9,000万米ドルに達すると予測され、予測期間2024年にはCAGR 7.4％で成長する見込みです。

疼痛管理薬は鎮痛薬とも呼ばれ、痛みを和らげることを目的とした医薬品です。非ステロイド性抗炎症薬（NSAIDs）、オピオイド、コルチコステロイド、筋弛緩薬、抗けいれん薬などです。

非ステロイド性抗炎症薬は軽度から中等度の痛みによく用いられ、炎症を抑える働きがあります。モルヒネやオキシコドンなどのオピオイド鎮痛薬は、中等度から重度の痛みに処方される強力な薬です。オピオイド鎮痛薬は脳内の特定の受容体に結合することで作用し、痛みの知覚を遮断します。抗けいれん薬、抗うつ薬は、補助鎮痛薬であり、神経痛や慢性疼痛症候群の管理に効果的です。

市場力学：

促進要因と抑制要因

慢性疼痛疾患の有病率の上昇。

疼痛治療薬は、変形性関節症、腰痛、神経障害性疼痛、線維筋痛症、がん性疼痛など、慢性的な痛みを伴う疾患への応用が主です。高齢化により、特定の慢性疼痛疾患の有病率が上昇しており、疼痛管理薬の需要が増加しています。

例えば、The Lancet Rheumatology誌に掲載された関節炎に関する世界の疾病負担調査によると、2020年には変形性関節症に罹患する人口が約5億9,500万人になると発表されています。2050年までに、変形性膝関節症は74.9％、変形性手関節症は48.6％、股関節の症例は78.6％、その他の変形性関節症は95.1％増加すると予想されています。

さらに、がんに関連した痛みは、鎮痛剤が広く処方される主な適応症のひとつです。さまざまながんの有病率は世界的に上昇しており、がん関連の痛みを経験する可能性のある患者数が増加しています。例えば、国際がん研究機関の予測によると、2030年にはがんの総発生数は2,400万人近くになり、2040年には3,000万人近くのがん患者が報告されると予想されています。

この憂慮すべき慢性適応症の増加は、疼痛管理薬に対する膨大な需要を生み出し、予測期間中の市場成長を促進すると思われます。

疼痛管理薬に関連する副作用が市場成長を抑制する可能性があります。

疼痛管理薬は急性から慢性の痛みを和らげるため、各個人の生活において重要な役割を果たしています。しかし、これらの薬剤、特にオピオイドやNSAIDの長期使用は、患者に深刻な副作用をもたらす可能性があります。主な副作用はオピオイドによるもので、乱用の可能性があり、患者の中毒を引き起こす可能性があります。その他の副作用としては、胃腸障害、心血管イベント、呼吸抑制などがあります。

非ステロイド性抗炎症薬は安全であると考えられているが、長期使用は重篤な胃腸障害を引き起こし、患者のQOLを損なう可能性があります。例えば、2024年3月にNature Scientific Reports誌に発表された研究では、NSAID使用者の13～15％が上部消化管不快感を経験し、消化性潰瘍の25％近くがNSAID使用により悪化すると述べられています。さらに、NSAIDsは心血管系イベントのリスクを25％増加させる。

これらの副作用は、急性期の使用者においては最小限のものであるが、慢性的な使用者においては重大な脅威となる可能性があります。このため、予測期間中、従来の疼痛管理薬の採用が減少する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 慢性疼痛疾患の罹患率が上昇しています。
    • 新薬開発の進展
  • 抑制要因
    • 薬に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• パイプライン分析
• 特許分析
• 規制分析

第6章 薬の種類別

• 非ステロイド性抗炎症薬
  • アセトアミノフェン
  • アスピリン
  • イブプロフェン
  • ナプロキセン
  • ジクロフェナク
  • セレコキシブ
  • その他
• オピオイド
  • オキシコドン
  • ヒドロコドン
  • コデイン
  • モルヒネ
  • フェンタニル
  • その他
• コルチコステロイド
  • デキサメタゾン
  • プレドニゾン
  • プレドニゾロン
  • その他
• 筋弛緩剤
• 抗けいれん薬
• その他

第7章 適応症別

• 関節炎の痛み
• 手術の痛み
• 怪我の痛み
• 腰痛
• 筋肉のけいれん
• 月経痛
• 頭痛と片頭痛
• がんの痛み
• 神経障害性疼痛
• 線維筋痛症
• その他

第8章 処方方法別

• 店頭
• 処方箋に基づく

第9章 流通チャネル別

• 病院薬局
• クリニック
• 小売薬局
• オンライン薬局
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Bayer AG
  • 会社概要
  • 薬剤タイプのポートフォリオと説明
  • 財務概要
  • 主な発展
• Haleon group of companies.
• Kenvue Brands LLC
• Purdue Pharma L.P.
• Teva Pharmaceuticals USA, Inc.
• Viatris Inc.
• Pfizer Inc.
• Abbott.
• Endo, Inc.
• Sun Pharmaceutical Industries Ltd.

第13章 付録

The global Pain management drugs market reached US$ 59.71 billion in 2023 and is expected to reach US$ 113.39 Billion by 2032, growing at a CAGR of 7.4% during the forecast period 2024-2032.

Pain management drugs also called analgesics, are medications aimed at alleviating pain. These are classified into several categories which majorly include non-steroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, muscle relaxants, anticonvulsants, etc.

NSAIDs are commonly used for mild to moderate pain and help reduce inflammation. Opioid analgesics, including morphine and oxycodone, are stronger medications prescribed for moderate to severe pain. They act by binding to specific receptors in the brain to block pain perception. Anticonvulsants, antidepressants adjuvant analgesics, and are effective for managing nerve pain and chronic pain syndromes.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic pain conditions.

Pain medications find their major applications in chronic, and painful conditions such as osteoarthritis, back pain, neuropathic pain, fibromyalgia, and cancer-related pain. Due to the aging population, the prevalence of certain chronic pain conditions is rising, which can increase the demand for pain management drugs.

For instance, as per the global disease burden study conducted on arthritis and published in The Lancet Rheumatology journal has stated that in 2020, there will be approximately 595 million population suffering from osteoarthritis. By 2050, knee osteoarthritis cases are expected to increase by 74.9%, hand osteoarthritis cases are expected to increase by 48.6%, hip cases will increase by 78.6%, and other types of osteoarthritis are expected to increase by 95.1%.

Moreover, cancer-related pain is one of the major indications where pain medications are widely prescribed. The prevalence of different cancers is rising globally, increasing the patient population who may experience cancer-related pain. For instance, as per the International Agency for Research on Cancer projections, in 2030, the total incidence cases of cancer are expected to be nearly 24 million, and in 2040, nearly 30 million cancer cases are expected to be reported.

This alarming rise in chronic indications creates a huge demand for pain management drugs, which will propel the market growth in the forecasted period.

The side effects associated with Pain management drugs may restrain the market growth.

Pain management drugs play a crucial role in every individual's life, as they alleviate acute to chronic pain. However, prolonged usage of these drugs, especially opioids, NSAID's may pose serious side effects to the patients. The major side effects are due to opioids which have abuse potential and can lead to addiction by patients. The other adverse effects include gastrointestinal issues, cardiovascular events, and respiratory depression.

Non-steroidal anti-inflammatory drugs are considered safe, however, long-term usage may lead to severe gastrointestinal events and may impair the patient's quality of life. For instance, a study published in Nature Scientific Reports in March 2024, has stated that 13-15% of NSAID users experience upper gastrointestinal discomfort, and nearly 25% of peptic ulcer cases are exacerbated by NSAID usage. In addition, NSAIDs are associated with a 25% increased risk of cardiovascular events.

These side effects are minimal in the acute usage population, however, they may pose a significant threat in chronic users. This may lead to decreased adoption of traditional pain management drugs in the forecasted period.

Segment Analysis

The global Pain management drugs market is segmented based on drug type, indication, mode of prescription, distribution channel, and region.

Non-steroidal anti-inflammatory Drugs are dominating the drug type segment with the highest market share.

Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of medications that reduce inflammation, relieve pain, and reduce body temperature and do not possess steroidal characteristics. Among NSAIDs, the commonly used drugs are ibuprofen, naproxen, and aspirin. These drugs act by inhibiting the cyclooxygenase (COX) pathway, with some drugs specifically active against COX1, some drugs active against COX2, and some non-specific.

The majority of the NSAIDs are available over-the-counter providing easy access to patients suffering from acute painful conditions such as headache, fever, body pains, etc. Moreover, The ability of NSAIDs to address both inflammation and pain makes them particularly valuable in treating conditions like arthritis.

Apart from the high usage rate for NSAIDs, manufacturers of these drugs are actively developing advanced formulations and taking initiatives to maximize the reach of these drugs to patients across the world. For instance, the Haleon group of companies, which is the major market player has launched several campaigns across the world to improve access to these basic medications. These campaigns have boosted the adoption of NSAIDs across several regions. To highlight, Haleon stated that in 2023 Panadol achieved strong growth in EMEA & LatAm as a result of the success of the new 'Release Starts Here' campaign. This campaign addressed specialist need states such as migraine, body pain, and headache. With the success of this campaign, the company further aims to fuel the growth of Panadol (Paracetamol-based pain reliever) by increasing our household penetration and accessibility and expanding systemic presence in other markets.

Geographical Analysis

North America is expected to hold a significant share of the Pain management drugs market.

North America currently holds a significant market share in the pain management drugs market due to various factors including, the rising prevalence of chronic diseases, well-developed healthcare infrastructure, strong presence of market players and branded drugs, ease of accessibility to these top-selling branded pain medication, rising prescription rate, and high cost of these medicines etc.

For instance, a study published in the Journal of International Medical Research in January 2023, has stated that nearly 5.3 million adults use prescription opioids frequently or daily to manage their chronic pain. Moreover, according to the Centers for Disease Control and Prevention (CDC), in 2023 approximately 150 million opioid prescriptions were dispensed to American citizens across the country.

In addition, a study published in the Anaesthesiology Journal in March 2024 stated that there was a significant increase in prescriptions of NSAIDs, acetaminophen, opioids, neuropathic agents, and muscle relaxants in the past decade till 2022.

The high cost of prescription and OTC medication in the region, especially in the U.S. is a significant contributor to the highest revenue generation by the market players. For instance, as per the U.S. Department of Health and Human Services- Assistant Secretary for Planning and Evaluation (ASPE), In 2022, the prices across all drugs including branded and generics were nearly 2.78 times in the U.S. as compared to other nations.

All these factors stated above are significant contributors to the region's dominance in the global pain management drugs market.

Competitive Landscape

The major global players in the Pain management drugs market are Bayer AG, Haleon Group of companies., Kenvue Brands LLC, Purdue Pharma L.P., Teva Pharmaceuticals USA, Inc., Viatris Inc., Pfizer Inc., Abbott., Endo, Inc., and Sun Pharmaceutical Industries Ltd. among others.

Emerging Players

The emerging players in the Pain management drugs market include Vertex Pharmaceuticals Incorporated, Neumentum Inc., and Tris Pharma, Inc. among others.

Key Developments

• In February 2024, the U.S. Food and Drug Administration (FDA) approved Naproxen Delayed-Release Tablets developed by ANI Pharmaceuticals, Inc. These delayed-release tablets are the generic version of the reference listed drug (RLD) EC-Naprosyn.
• In April 2024, Glenmark Pharmaceuticals Ltd. Received the U.S. Food and Drug (FDA) approval for Acetaminophen and Ibuprofen Tablets generic tablets for commercialization in the U.S. market. These drugs are bioequivalent to Haleon's Advil(R)2 Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC).
• Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and Drug Type pipelines, and forecasts upcoming pharmaceutical advancements.
• Drug Type Performance & Market Positioning: Analyzes Drug Type performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into drug-type development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Drug Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance Drug Type safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Pain management drugs market report would provide approximately 70 tables, 74 figures, and 230 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Indication
• 3.3. Snippet by Mode of Prescription
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising prevalence of chronic pain conditions.
    • 4.1.1.2. Rising development of novel drugs
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with the drugs
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Patent Analysis
• 5.6. Regulatory Analysis

6. By Drug Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 6.1.2. Market Attractiveness Index, By Drug Type
• 6.2. Non-Steroidal Anti-Inflammatory Drugs*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Acetaminophen
  • 6.2.4. Aspirin
  • 6.2.5. Ibuprofen
  • 6.2.6. Naproxen
  • 6.2.7. Diclofenac
  • 6.2.8. Celecoxib
  • 6.2.9. Others
• 6.3. Opioids
  • 6.3.1. Oxycodone
  • 6.3.2. Hydrocodone
  • 6.3.3. Codeine
  • 6.3.4. Morphine
  • 6.3.5. Fentanyl
  • 6.3.6. Others
• 6.4. Corticosteroids
  • 6.4.1. Dexamethasone
  • 6.4.2. Prednisone
  • 6.4.3. Prednisolone
  • 6.4.4. Others
• 6.5. Muscle Relaxants
• 6.6. Anticonvulsant Drugs
• 6.7. Others

7. By Indication

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.1.2. Market Attractiveness Index, By Indication
• 7.2. Arthritis Pain*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Surgery Pain
• 7.4. Injury Pain
• 7.5. Back Pain
• 7.6. Muscle Spasms
• 7.7. Menstrual Pain
• 7.8. Headaches & Migraine
• 7.9. Cancer Pain
• 7.10. Neuropathic Pain
• 7.11. Fibromyalgia
• 7.12. Others

8. By Mode of Prescription

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 8.1.2. Market Attractiveness Index, By Mode of Prescription
• 8.2. Over-the-Counter*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Prescription Based

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Clinics
• 9.4. Retail Pharmacies
• 9.5. Online Pharmacies
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Bayer AG*
  • 12.1.1. Company Overview
  • 12.1.2. Drug Type Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Haleon group of companies.
• 12.3. Kenvue Brands LLC
• 12.4. Purdue Pharma L.P.
• 12.5. Teva Pharmaceuticals USA, Inc.
• 12.6. Viatris Inc.
• 12.7. Pfizer Inc.
• 12.8. Abbott.
• 12.9. Endo, Inc.
• 12.10. Sun Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us